Patients with ERα-expressing prostate cancers might best first be directed to treatments such as cytotoxic chemotherapy or radionuclide therapy rather than AR-targeted therapies, especially if residual serum or tissue levels of estrogen are sufficient to activate ERα. This evidence concerns the gene AR and prostate carcinoma.